Clinical Trials
Braintumor Website

These trials were the most recently added or updated

NCT Trial Name# of CentersLast Updated

NCT02831959

  Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)
1312/16/2016

NCT02764151

  First in Patient Study for PF-06840003 in Malignant Gliomas
712/16/2016

NCT02661282

  Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients
112/16/2016

NCT02658279

  Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
412/16/2016

NCT02192359

  Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
112/16/2016

NCT01988675

  MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier
112/16/2016

NCT01622868

  Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
312/16/2016

NCT01494662

  HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
1112/16/2016

NCT00840047

  Methionine PET/CT Studies In Patients With Cancer
112/16/2016

NCT02798406

  Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
412/15/2016

NCT02698254

  Pilot Trial of Dose-Volume Constraints for Reirradiation of Recurrent Brain Tumors
112/15/2016

NCT02681549

  Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
112/15/2016

NCT02589522

  VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer
312/15/2016

NCT02573324

  A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
15612/15/2016

NCT02568267

  Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
9312/15/2016

NCT02433171

  Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery
112/15/2016

NCT02005614

  A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
112/15/2016

NCT02993146

  Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
112/14/2016

NCT02632370

  5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
412/14/2016

NCT02276053

  Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors
2812/14/2016

NCT02157103

  A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
212/14/2016

NCT02153957

  Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors
112/14/2016

NCT02125786

  A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
112/14/2016

NCT02015117

  Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
212/14/2016

NCT02774681

  Palbociclib in Treating Patients With Metastatic HER-2 Positive or Triple-Negative Breast Cancer With Brain Metastasis
112/13/2016

NCT02663271

  TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
112/13/2016

NCT01851733

  MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme
112/13/2016

NCT01528046

  Metformin in Children With Relapsed or Refractory Solid Tumors
912/13/2016

NCT01454596

  CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
112/13/2016

NCT02650752

  Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
712/12/2016

NCT02605746

  Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis
112/12/2016

NCT02395692

  Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma
712/12/2016

NCT02375841

  Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers
312/12/2016

NCT02334722

  1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
112/12/2016

NCT02271711

  Fourth Ventricle Infusions of Autologous Ex Vivo Expanded NK Cells in Children With Recurrent Posterior Fossa Tumors
112/12/2016

NCT02180217

  Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
7212/12/2016

NCT02095132

  WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
712/12/2016

NCT02085304

  Tumor Resection and Gliadel┬« Wafers, Followed by Temodar┬« With Standard Radiation or GammaKnife┬« for New GBM
112/12/2016

NCT02060383

  Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
4412/12/2016

NCT02992015

  Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
112/09/2016

NCT02940483

  Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma
112/09/2016

NCT02718443

  VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
112/09/2016

NCT02343991

  Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound
112/09/2016

NCT01808820

  Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
112/09/2016

NCT02864368

  Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
112/08/2016

NCT02709889

  Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
1612/08/2016

NCT02659800

  IL-7 in Increasing Low CD4 Counts After Concurrent Radiation and Temozolomide Treatment in Patients With High Grade Gliomas
612/08/2016

NCT02658981

  Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma
1012/08/2016

NCT02546102

  Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
6012/08/2016

NCT02335918

  A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
1012/08/2016



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites